Skip to main content
. 2021 Jun 6;38(8):e14607. doi: 10.1111/dme.14607

TABLE 1.

Baseline characteristics of study participants stratified according to the diabetic status

Total NGL Prediabetes Diabetes
N = 405,487 N = 265,708 (65.5%) N = 116,951 (28.8%) N = 22,828 (5.6%)
Man (%) 61.9 54.2 75.6 82.2
Age (years) 50 (43–57) 48 (42–55) 53 (46–59) 57 (51–63)
BMI (kg/m2) 22.6 (20.6–24.9) 22.0 (20.1–24.1) 23.6 (21.7–25.9) 25.0 (22.7–27.8)
WC (cm) 81.6 (75.5–87.7) 79.8 (74.0–85.5) 84.5 (79.2–90.2) 88.3 (82.5–95.2)
FPG (mmol/L) 5.28 (4.94–5.72) 5.06 (4.83–5.28) 5.83 (5.67–6.11) 7.50 (7.00–8.44)
HbA1c (mmol/mol) 37 (34–39) 36 (33–38) 38 (36–41) 51 (45–57)
HbA1c (%) 5.5 (5.3–5.7) 5.4 (5.2–5.6) 5.6 (5.4–5.9) 6.8 (6.3–7.4)
Systolic BP (mmHg) 117 (106–128) 114 (104–125) 122 (112–133) 126 (116–137)
Diastolic BP (mmHg) 74 (66–82) 71 (64–80) 78 (70–85) 79 (71–86)
Antihypertensive medication (%) 13.8 8.9 19.6 40.6
Prevalence of hypertension (%) 24.2 17.1 34.6 54.0
Triglycerides (mmol/L) 1.01 (0.71–1.46) 0.92 (0.66–1.32) 1.18 (0.84–1.69) 1.30 (0.90–1.90)
HDL cholesterol (mmol/L) 1.58 (1.32–1.89) 1.63 (1.37–1.94) 1.50 (1.27–1.81) 1.37 (1.17–1.66)
LDL cholesterol (mmol/L) 3.16 (2.64–3.68) 3.11 (2.59–3.63) 3.26 (2.77–3.81) 3.08 (2.56–3.60)
Lipid‐lowering medication (%) 10.0 6.8 12.6 34.2
Prevalence of dyslipidaemia (%) 46.1 39.6 56.4 68.8
eGFR (ml min−1 1.73 m−2) 77.3 (69.9–86.1) 77.8 (71.4–86.7) 76.0 (69.0–84.6) 77.8 (69.8–87.6)
Past history of
Cardiac disease (%) 2.3 1.8 2.9 5.7
Stroke (%) 1.0 0.8 1.3 2.5
Current smokers (%) 21.8 21.1 22.6 26.2

Continuous variables are expressed as median (interquartile range).

Abbreviations: BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; FPG, fasting plasma glucose; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; NGL, normal glucose level; WC, waist circumference.